Cargando…

Xanthine oxidase inhibition by febuxostat attenuates stress-induced hyperuricemia, glucose dysmetabolism, and prothrombotic state in mice

Chronic stress is closely linked to the metabolic syndrome, diabetes, hyperuricemia and thromboembolism, but the mechanisms remain elusive. We reported recently that stress targets visceral adipose tissue (VAT), inducing lipolysis, low-grade inflammation with production of inflammatory adipokines, m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yisireyili, Maimaiti, Hayashi, Motoharu, Wu, Hongxian, Uchida, Yasuhiro, Yamamoto, Koji, Kikuchi, Ryosuke, Shoaib Hamrah, Mohammad, Nakayama, Takayuki, Wu Cheng, Xian, Matsushita, Tadashi, Nakamura, Shigeo, Niwa, Toshimitsu, Murohara, Toyoaki, Takeshita, Kyosuke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5430858/ https://www.ncbi.nlm.nih.gov/pubmed/28455534 http://dx.doi.org/10.1038/s41598-017-01366-3

Ejemplares similares

Indole-3-propionic acid suppresses indoxyl sulfate-induced expression of fibrotic and inflammatory genes in proximal tubular cells
por: Yisireyili, Maimaiti, et al.
Publicado: (2017)

Indoxyl Sulfate-induced Vascular Calcification is mediated through Altered Notch Signaling Pathway in Vascular Smooth Muscle Cells
por: Yamaguchi, Kazutoshi, et al.
Publicado: (2020)

Associations between proteinuria and cardiovascular risk factors among hypertensive patients in Andkhoy, Afghanistan
por: Shoaib Hamrah, Mohammad, et al.
Publicado: (2016)

Indoxyl Sulfate-Induced Activation of (Pro)renin Receptor Promotes Cell Proliferation and Tissue Factor Expression in Vascular Smooth Muscle Cells
por: Yisireyili, Maimaiti, et al.
Publicado: (2014)

Anxiety and Depression among Hypertensive Outpatients in Afghanistan: A Cross-Sectional Study in Andkhoy City
por: Hamrah, Mohammad Shoaib, et al.
Publicado: (2018)

Left ventricular hypertrophy and proteinuria in patients with essential hypertension in Andkhoy, Afghanistan
por: Shoaib Hamrah, Mohammad, et al.
Publicado: (2018)

Stress Augments Insulin Resistance and Prothrombotic State: Role of Visceral Adipose-Derived Monocyte Chemoattractant Protein-1
por: Uchida, Yasuhiro, et al.
Publicado: (2012)

Cardio-renal protective effect of the xanthine oxidase inhibitor febuxostat in the 5/6 nephrectomy model with hyperuricemia
por: Omizo, Hiroki, et al.
Publicado: (2020)

Management of hyperuricemia in gout: focus on febuxostat
por: Reinders, Mattheus K, et al.
Publicado: (2010)

Side Effects and Interactions of the Xanthine Oxidase Inhibitor Febuxostat
por: Jordan, Andreas, et al.
Publicado: (2018)

Notch1 haploinsufficiency in mice accelerates adipogenesis
por: Yamaguchi, Kazutoshi, et al.
Publicado: (2021)

Angiotensin II Receptor Blocker Ameliorates Stress-Induced Adipose Tissue Inflammation and Insulin Resistance
por: Hayashi, Motoharu, et al.
Publicado: (2014)

Xanthine Oxidase Inhibition by Febuxostat Attenuates Experimental Atherosclerosis in Mice
por: Nomura, Johji, et al.
Publicado: (2014)

The potential renoprotection of xanthine oxidase inhibitors: Febuxostat versus allopurinol
por: Ryu, Dong-Ryeol
Publicado: (2017)

Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial
por: Tanaka, Atsushi, et al.
Publicado: (2020)

Indoxyl sulfate, a uremic toxin, downregulates renal expression of Nrf2 through activation of NF-κB
por: Bolati, Dilinaer, et al.
Publicado: (2013)

Febuxostat in the management of hyperuricemia and chronic gout: a review
por: Hu, Miao, et al.
Publicado: (2008)

Febuxostat: the evidence for its use in the treatment of hyperuricemia and gout
por: Gaffo, Angelo L, et al.
Publicado: (2010)

Febuxostat for Hyperuricemia in Patients with Advanced Chronic Kidney Disease
por: Akimoto, Tetsu, et al.
Publicado: (2014)

Febuxostat: A Novel Agent for Management of Hyperuricemia in Gout
por: Bisht, Manisha, et al.
Publicado: (2011)

Association between Helicobacter pylori Infection and Cardiovascular Risk Factors among Patients in the Northern Part of Afghanistan: a Cross-Sectional Study in Andkhoy City
por: Hamrah, Mohammad Shoaib, et al.
Publicado: (2018)

The Xanthine Oxidase Inhibitor Febuxostat Suppresses Adipogenesis and Activates Nrf2
por: Higa, Yoshiki, et al.
Publicado: (2023)

Advances in the management of gout: Critical appraisal of febuxostat in the control of hyperuricemia
por: Beara-Lasic, Lada, et al.
Publicado: (2010)

Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients
por: Sofue, Tadashi, et al.
Publicado: (2014)

SAT-079 Renal Protective Effects Of Topiroxostat And Febuxostat In Hypertensives With Hyperuricemia.
por: Satoh, Fumitoshi, et al.
Publicado: (2019)

Comparative effects of topiroxostat and febuxostat on arterial properties in hypertensive patients with hyperuricemia
por: Kario, Kazuomi, et al.
Publicado: (2021)

The Effects of Febuxostat on Urine NGAL and Urine KIM-1 in Patients with Hyperuricemia
por: Tang, Yushang, et al.
Publicado: (2022)

Febuxostat, a Xanthine Oxidase Inhibitor, Decreased Macrophage Matrix Metalloproteinase Expression in Hypoxia
por: Wei, Shuoyu, et al.
Publicado: (2020)

Rationale and design of a multicenter randomized study for evaluating vascular function under uric acid control using the xanthine oxidase inhibitor, febuxostat: the PRIZE study
por: Oyama, Jun-ichi, et al.
Publicado: (2016)

Cathepsin S Activity Controls Injury-Related Vascular Repair in Mice via the TLR2-Mediated p38MAPK and PI3K−Akt/p-HDAC6 Signaling Pathway
por: Wu, Hongxian, et al.
Publicado: (2016)

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial
por: Becker, Michael A, et al.
Publicado: (2010)

Retracted: The Effects of Febuxostat on Urine NGAL and Urine KIM-1 in Patients with Hyperuricemia
por: Healthcare Engineering, Journal of
Publicado: (2023)

Comparison of Febuxostat and Allopurinol in the Treatment of Patients with Chronic Kidney Disease Stage 3∼5 with Hyperuricemia
por: Liao, Zhimin, et al.
Publicado: (2022)

Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview
por: Chen, Changyi, et al.
Publicado: (2016)

The Role of Oxidative Stress in Hyperuricemia and Xanthine Oxidoreductase (XOR) Inhibitors
por: Liu, Ning, et al.
Publicado: (2021)

Indoxyl Sulfate Downregulates Expression of Mas Receptor via OAT3/AhR/Stat3 Pathway in Proximal Tubular Cells
por: Ng, Hwee-Yeong, et al.
Publicado: (2014)

Switching from allopurinol to febuxostat: efficacy and safety in the treatment of hyperuricemia in renal transplant recipients
por: Li, Yanchun, et al.
Publicado: (2019)

Different inhibitory potency of febuxostat towards mammalian and bacterial xanthine oxidoreductases: insight from molecular dynamics
por: Kikuchi, Hiroto, et al.
Publicado: (2012)

Febuxostat, a novel xanthine oxidoreductase inhibitor, improves hypertension and endothelial dysfunction in spontaneously hypertensive rats
por: Shirakura, Takashi, et al.
Publicado: (2016)

Clinical Significance of Elevated Xanthine Dehydrogenase Levels and Hyperuricemia in Patients with Sepsis
por: Matsuoka, Masaru, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vo9q4j08vqip6ks2vssf9adrav